Integrated Therapeutics Group
11
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
27.3%
3 terminated/withdrawn out of 11 trials
72.7%
-13.8% vs industry average
91%
10 trials in Phase 3/4
88%
7 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Role: collaborator
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Role: collaborator
Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
Role: collaborator
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
Role: collaborator
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
Role: collaborator
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
Role: collaborator
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
Role: collaborator
Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
Role: collaborator
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
Role: collaborator
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
Role: collaborator
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Role: collaborator
All 11 trials loaded